Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

S 095033

Next Previous
Drug Profile

S 095033

Alternative Names: AG-270; S-095033; S-95033

Latest Information Update: 07 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Agios Pharmaceuticals
  • Developer Agios Pharmaceuticals; Servier
  • Class Antineoplastics; Ethers; Ketones; Morpholines; Pyridazines; Small molecules
  • Mechanism of Action MAT2A protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Adenocarcinoma; Squamous cell cancer
  • Phase I Lymphoma; Solid tumours

Most Recent Events

  • 26 Jun 2023 Agios Pharmaceuticals terminates a phase I trial in Lymphoma, Solid tumours (Late-stage disease, Second-line therapy or greater, Monotherapy, Combination therapy) in USA, Spain, France (PO) (NCT03435250)
  • 20 Apr 2023 Agios Pharmaceuticals completes a phase I trial in Lymphoma, Solid tumours (Late-stage disease, Second-line therapy or greater, Monotherapy, Combination therapy) in USA, Spain, France (PO) (NCT03435250)
  • 07 Dec 2022 Institut de Recherches Internationales Servier in collaboration with Servier withdrews a phase I/II trial prior to enrollment in Oesophageal cancer (Combination therapy) (Late stage disease) (Metastatic disease) (IV) due to strategic development reasons (NCT05312372)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top